## Contents

Preface xi  
Contributors xiii  
Acknowledgments xv  

I  
DEVELOPMENT OF BIOPHARMACEUTICALS DEFINED AS NOVEL BIOLOGICS  

1. Overview of Biopharmaceuticals and Comparison with Small-molecule Drug Development  
THERESA REYNOLDS, CHRISTINA DE ZAFRA, AMY KIM, THOMAS R. GELZLEICHTER  
Introduction 3  
History and Evolution of Biopharmaceuticals 4  
Development of Diverse Biopharmaceutical Modalities 7  
Comparison of Small-Molecule Drugs to Biopharmaceuticals 21  
Summary 27  
References 27  

2. Regulatory Guidelines and their Application in the Nonclinical Evaluation of Biological Medicines  
MARQUE D. TODD, MAGGIE DEMPSTER  
Introduction 35  
Species Selection 38  
Study Design Considerations for Repeat-Dose Studies 43  
Immunogenicity 47  
Reproductive and Developmental Toxicity 50  
Genotoxicity and Carcinogenicity 54  
Special Considerations for Anticancer Drugs 57  
First-in-Human (FiH) Clinical Trial 59  
Summary 62  
References 62  

3. Early De-risking Strategy for Novel Biotherapeutics  
PADMA KUMAR NARAYANAN, RAFAEL PONCE, BETH HINKLE  
Introduction 65  
Establishing A Safety Profile for Biotherapeutics 66  
General Safety Considerations Related to Biotherapeutics 67  
Progress in Evaluation of Immunotoxicity 78  
Can We Better Address Potential Off-Target Toxicity? 84  
Summary 90  
References 90  

4. Novel Biopharmaceuticals: Pharmacokinetics, Pharmacodynamics, and Bioanalytics  
MELINDA MARIAN, WOLFGANG SEGHEZZI  
Introduction 97  
Absorption, Distribution and Elimination of Biopharmaceuticals 97  
Disposition of Modified Molecules 106  
“Metabolism” and Biodistribution for Biopharmaceuticals 108  
Immunogenicity and impacts on PK and biodistribution 110  
Pharmacokinetics and Pharmacodynamics 110  
Preclinical to Clinical Translation 113  
Bioanalytics 115  
Drug Assays 124  
Biomarkers: Target Engagement Assays 125
II
DEVELOPMENT OF BIOSIMILARS

5. Overview of Biosimilar Therapeutics
   DANUTA J. HERZYK
   Introduction 141
   The Concept of Biosimilars 142
   General Considerations for Development of Biosimilars 144
   Biosimilar Candidates Based on Modality and Therapeutic Class 148
   Summary 155
   References 156

6. Regulatory Standards for the Approval of Biosimilar Products: A Global Review
   BARBARA MOUNHO-ZAMORA
   Introduction 159
   European Union—Pioneer for the First Regulatory Pathway for Biosimilar Products 161
   The World Health Organization Guidance on Biosimilars 169
   Regulatory Pathway for Biosimilar Products in the United States 171
   Biosimilar Pathways in Other Regions 178
   Summary 182
   References 182

7. Early Characterization of Biosimilar Therapeutics
   THOMAS R. GELZLEICHTER
   Introduction 185
   Recombinant Insulins 186
   Recombinant Human Growth Hormone 189
   Recombinant Erythropoietins 192
   Recombinant Granulocyte Colony-Stimulating Factor 195

III
VACCINES

8. Introduction to Vaccines and Adjuvants
   DEBORAH L. NOVICKI
   Introduction 213
   The History of Vaccines 214
   The Impact of Vaccines on Human Health 215
   Advancements in Vaccines Technologies 216
   Advancements in Adjuvant Technologies 216
   Approved Infectious Disease Vaccines and Diseases for Which Preventive Vaccines are Still Needed 218
   Therapeutic Vaccines 219
   Product Complexity From a Quality Perspective 220
   Nonclinical Testing 220
   Clinical Testing 221
   Vaccine Development Using the Animal Rule 221
   The Anti-Vaccines Movement and Misperceptions About Vaccines and Their Safety 222
   Summary 223
   References 223

9. Global Regulatory Guidelines for Vaccines
   LISA M. PLITNICK
   Introduction 225
   Toxicity Assessment 229
   Additional Toxicity Assessments 231
   Special Considerations 235
   Formulation/Delivery Devices 236
   Alternate Routes of Administration 236
   Special Considerations for Particular Types of Vaccines 237
   Summary 239
   References 240
10. Special Considerations for the Nonclinical Safety Assessment of Vaccines

JAYANTHI J. WOLF

Introduction 243
De-risking Strategies for Vaccines 244
Pharmacokinetics and Pharmacodynamics Assessments 248
Differences in the Nonclinical Safety Assessment of Vaccines and Biopharmaceutical Drugs 251
Summary 252
References 253

IV
SPECIALTY BIOLOGICS AND INDICATIONS

11. Turning the Corner with Viral-based Gene Therapy—Development of the Rogue Biopharmaceutical

TIMOTHY K. MACLACHLAN

Introduction 259
A History and Primer of Gene Therapy 260
The Process of Getting Genes into Cells 265
Health Authority Regulation of Gene Therapy Products 271
Nonclinical Safety Studies and Regulatory Guidance 275
Summary 282
References 282

12. Blood Products

INGE A. IVENS, VIKRAM ARORA

Introduction 287
Plasma-Derived Blood Products 289
Blood Products Derived from Recombinant Technologies 293
Summary 300
References 300

13. Biological Therapies for Cancer

KAREN D. PRICE, GAUTHAM K. RAO

Introduction 303
Global Regulatory Guidances 304

14. Nonclinical Development of Multi-targeting Biopharmaceuticals

RODNEY A. PRELL, DONNA W. LEE, WENDY G. HALPERN, ANU V. CONNOR

Introduction 343
Scientific Rationale for Multi-Targeting Biopharmaceuticals (MTBs) 344
Evolution of Technology Platforms 345
General Challenges and Considerations 348
Summary of Challenges 354
T Cell-Dependent Bispecific Antibody (TDB) Biotherapeutics 355
Dual-Targeting Antibodies 362
Summary 368
References 369

15. Considerations in the Development of Pluripotent Stem Cell-based Therapies

RANIA NASIS, JUSTINE J. CUNNINGHAM, EUGENE P. BRANDON, JOY A. CAVAGNARO

Introduction 373
Early Decisions 378
Nonclinical Development 388
Translating Preclinical Data to Clinical Application 399
Global Regulatory Guidance 400
Summary 403
References 404

Index 409